» Articles » PMID: 19741531

Pharmacology and Treatment of Neuropathic Pains

Overview
Specialty Neurology
Date 2009 Sep 11
PMID 19741531
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: This review briefly discusses the definition and clinical presentation of neuropathic pain and highlights recent advances in the treatment of neuropathic pain.

Recent Findings: Recent publications have confirmed the efficacy of tricyclic antidepressants, gabapentin, pregabalin, opioids, and tramadol for various neuropathic pain conditions. Selective serotonin noradrenaline reuptake inhibitors have been found to reduce pain in painful neuropathy. The new anticonvulsant lacosamide may have some effect in painful polyneuropathy, whereas levetiracetam has failed to relieve postmastectomy and spinal cord injury pain. The role of the old anticonvulsant phenytoin is still unsettled. A recent trial has found an effect of cannabinoids also in peripheral neuropathic pain. Various topical treatments such as topical lidocaine, topically applied capsaicin in high concentrations (8%), and botulinum toxin have recently been shown to have a pain-relieving effect in various peripheral neuropathic pain conditions. Spinal cord and transcranial magnetic stimulation are stimulation therapies with some evidence for efficacy.

Summary: Treating neuropathic pain remains a great challenge, and the treatment has to be individualized to the single patient, taking into account side effects, pain type, comorbidities, and drug interactions.

Citing Articles

Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment.

Manengu C, Zhu C, Zhang G, Tian M, Lan X, Tao L Curr Neuropharmacol. 2024; 23(3):276-294.

PMID: 39411936 PMC: 11808587. DOI: 10.2174/1570159X23666241011163035.


Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes.

Braffett B, El Ghormli L, Albers J, Feldman E, Herman W, Gubitosi-Klug R Diabetes Care. 2024; 47(9):1559-1567.

PMID: 38300889 PMC: 11362121. DOI: 10.2337/dc23-1749.


An anchor-tether 'hindered' HCN1 inhibitor is antihyperalgesic in a rat spared nerve injury neuropathic pain model.

Tibbs G, Uprety R, Warren J, Beyer N, Joyce R, Ferrer M Br J Anaesth. 2023; 131(4):745-763.

PMID: 37567808 PMC: 10541997. DOI: 10.1016/j.bja.2023.06.067.


Diagnosis and Management of Neuropathic Pain in Spine Diseases.

Bielewicz J, Kamieniak M, Szymoniuk M, Litak J, Czyzewski W, Kamieniak P J Clin Med. 2023; 12(4).

PMID: 36835916 PMC: 9961043. DOI: 10.3390/jcm12041380.


Vesicular nucleotide transporter is a molecular target of eicosapentaenoic acid for neuropathic and inflammatory pain treatment.

Kato Y, Ohsugi K, Fukuno Y, Iwatsuki K, Harada Y, Miyaji T Proc Natl Acad Sci U S A. 2022; 119(30):e2122158119.

PMID: 35858418 PMC: 9335333. DOI: 10.1073/pnas.2122158119.